The Funding of Biopharmaceutical Research and Development

The funding of biopharmaceutical research and development provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market sector. It addresses both private and public funding sources available in the US and internationally. The biopharmaceutical market is among the most research-intensive market sectors globally. Clinical researchers face a multitude of public and private funding options with respect to bringing their idea or innovation to market. These funding options are continually changing and complex, and are expected to decrease in the near future. A lack of understanding of the scale, scope, and inner workings of the funding aspects of R&D can, at times, act as a barrier for all involved, and can slow down or even eliminate the R&D process. The book lessens these barriers by describing the theoretical underpinnings, present practice, and trends in R&D funding in this market sector, both in the US and internationally. This includes a review and discussion of public-private partnership activity and their inner-workings, noting the complementary relationship between public and private funding. The book also contains an overview of the inner-workings of strategic alliance activity, including the advantages and disadvantages for each party. It goes on to provide an outline of venture capital activity, detailing the methods by which venture capital firms raise capital and are organized, a description of the venture capital-entrepreneur arrangement, and the effects of this arrangement. The book also presents an overview of the IPO process and the various fates of firms going public. Presents a comprehensive view of the funding issues of R&D in this market sector, adopting a theory-to-practice approach A comprehensive and analytical review of the biopharmaceutical R&D literature and practice An overview of the various and competing/complementary theories of the firm and valuation methods as they apply to biopharmaceutical R&D

Produk Detail:

  • Author : David R Williams
  • Publisher : Elsevier
  • Pages : 284 pages
  • ISBN : 1908818387
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKThe Funding of Biopharmaceutical Research and Development

The Funding of Biopharmaceutical Research and Development

The Funding of Biopharmaceutical Research and Development
  • Author : David R Williams
  • Publisher : Elsevier
  • Release : 31 October 2013
GET THIS BOOKThe Funding of Biopharmaceutical Research and Development

The funding of biopharmaceutical research and development provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market sector. It addresses both private and public funding sources available in the US and internationally. The biopharmaceutical market is among the most research-intensive market sectors globally. Clinical researchers face a multitude of public and private funding options with respect to bringing their idea or innovation to market. These funding options are continually changing and

Making Medicines Affordable

Making Medicines Affordable
  • Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
  • Publisher : National Academies Press
  • Release : 01 March 2018
GET THIS BOOKMaking Medicines Affordable

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs

Modern Strategy for Preclinical Pharmaceutical R&D

Modern Strategy for Preclinical Pharmaceutical R&D
  • Author : David Cavalla
  • Publisher : John Wiley & Sons
  • Release : 07 October 1997
GET THIS BOOKModern Strategy for Preclinical Pharmaceutical R&D

The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in

Strategies to Leverage Research Funding

Strategies to Leverage Research Funding
  • Author : Institute of Medicine,Board on Health Sciences Policy,Medical Follow-Up Agency,Committee on Alternative Funding Strategies for DOD's Peer Reviewed Medical Research Programs
  • Publisher : National Academies Press
  • Release : 27 November 2004
GET THIS BOOKStrategies to Leverage Research Funding

Since 1992 the Department of Defense (DOD), through the U.S. Army Medical Research and Material Command, has received congressionally earmarked appropriations for programs of biomedical research on prostate, breast, and ovarian cancer; neurofibromatosis; tuberous sclerosis; and other health problems. Appropriations for these Congressionally Directed Medical Research Programs are used to support peer reviewed extramural research project, training, and infrastructure grants. Congress has become concerned about funding increases for these programs given current demands on the military budget. At the request

Biotech Industry

Biotech Industry
  • Author : Bryan Bergeron,Paul Chan
  • Publisher : John Wiley & Sons
  • Release : 12 April 2004
GET THIS BOOKBiotech Industry

"The biotech industry is a complex, rapidly evolving, and criticalindustry. The industry holds great commercial and societal promise,but it is also filled with hype, confusion, and risks. Bergeron andChan do a remarkable job of providing a sweeping insightful, andprobing assessment of the current state and likely evolution ofthis global industry. This book is essential reading for theexecutive who desires a thorough understanding of this business andits potential."--John P. Glasser, Vice President and ChiefInformation Offers, Partners Healthcare System, Inc. "

Re-inventing Drug Development

Re-inventing Drug Development
  • Author : Jeffrey S. Handen
  • Publisher : CRC Press
  • Release : 28 October 2014
GET THIS BOOKRe-inventing Drug Development

The biopharmaceutical industry has entered an era of unprecedented change and challenge, characterized by increasing pricing pressures, rising rates of attrition in the product development lifecycle, and decreasing scientific innovation. The most successful products are losing patent protection, and pipelines have been unable to fill the gap. This book explores the evolving definition of innovation in therapeutic product development and begins to examine its effects on the life sciences R&D industry. Historically, scientific innovation alone was sufficient to maintain

Improving and Accelerating Therapeutic Development for Nervous System Disorders

Improving and Accelerating Therapeutic Development for Nervous System Disorders
  • Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
  • Publisher : National Academies Press
  • Release : 06 February 2014
GET THIS BOOKImproving and Accelerating Therapeutic Development for Nervous System Disorders

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective

Rare Diseases and Orphan Products

Rare Diseases and Orphan Products
  • Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Accelerating Rare Diseases Research and Orphan Product Development
  • Publisher : National Academies Press
  • Release : 03 April 2011
GET THIS BOOKRare Diseases and Orphan Products

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

The Price of Global Health

The Price of Global Health
  • Author : Ed Schoonveld
  • Publisher : Routledge
  • Release : 24 February 2016
GET THIS BOOKThe Price of Global Health

Public debate on the rising cost of new biotechnology drug treatments has intensified over the last few years as healthcare budget pressures have mounted under a strained economy. Meanwhile, the demand for new, effective medical and drug treatments continues to rise as unhealthy lifestyles cause further increases in diabetes and cardiovascular disease. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it

Entrepreneurship in Biotechnology

Entrepreneurship in Biotechnology
  • Author : Martin Grossmann
  • Publisher : Springer Science & Business Media
  • Release : 06 December 2012
GET THIS BOOKEntrepreneurship in Biotechnology

Research and development of novel medicines for human therapy commonly takes over a decade before significant revenues from sales are forthcoming. How can biotechnology companies be founded and grow successfully in an industry with such extended innovation processes? The book investigates this problem and distinguishes three growth phases: From incorporation and start-up through collaborative R&D with large pharmaceutical firms to value creation from R&D pipelines to Public Offerings and product marketing. In this book a dynamic simulation model

Valuing Pharmaceutical Companies

Valuing Pharmaceutical Companies
  • Author : Karen Beynon,Andrew Porter
  • Publisher : Woodhead Publishing
  • Release : 03 July 2000
GET THIS BOOKValuing Pharmaceutical Companies

The pharmaceutical sector offers some of the most exciting financial and business opportunities today. This essential and practical guide gives you all the tools you need to assess such opportunities. The second edition of the respected Pharmaceutical Equities, it has been thoroughly revised and updated to reflect the changes, especially in life sciences, since the first edition. The book is international in outlook, and explains the rules of the game not just for wise investing, but also for understanding how

The Changing Economics of Medical Technology

The Changing Economics of Medical Technology
  • Author : Institute of Medicine,Committee on Technological Innovation in Medicine
  • Publisher : National Academies Press
  • Release : 01 February 1991
GET THIS BOOKThe Changing Economics of Medical Technology

Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policies--as well as the involvement of numerous government agencies--affect

Federal R&d, Drug Discovery, and Pricing

Federal R&d, Drug Discovery, and Pricing
  • Author : Wendy H. Schacht
  • Publisher : DIANE Publishing
  • Release : 10 October 2012
GET THIS BOOKFederal R&d, Drug Discovery, and Pricing

Public interest in approaches that might provide prescription drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. The government traditionally funds R&D to meet the mission requirements of the federal departments and agencies. It also supports work in areas where there is an identified need for research, primarily basic research, not being performed in the private sector. Congressional initiatives have